APO Research
Talk to an analyst

APO RESEARCH · REPORT

Beta-lactam and Beta-lactamase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Beta-lactam and Beta-lactamase Inhibitors Industry Growth and Trends Forecast to 2032

22 December 2025113 pages

Choose your research edition.

Industry ResearchBeta-lactam and Beta-lactamase Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Beta-lactam and Beta-lactamase Inhibitors Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Beta-lactam and Beta-lactamase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Beta-lactam and Beta-lactamase Inhibitors Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Beta-lactam and Beta-lactamase Inhibitors Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Beta-lactam and Beta-lactamase Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Beta-lactam and Beta-lactamase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Beta-lactam and Beta-lactamase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Beta-lactam and Beta-lactamase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma and Wockhardt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Beta-lactam and Beta-lactamase Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Beta-lactam and Beta-lactamase Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (M Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Beta-lactam and Beta-lactamase Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Beta-lactam and Beta-lactamase Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Beta-lactam and Beta-lactamase Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Beta-lactam and Beta-lactamase Inhibitors Market by Company

Pfizer

Novartis (Sandoz)

TEVA

Merck

AbbVie (Allergan)

Sumitomo Dainippon

Hikma

Aurobindo Pharma

Wockhardt

Lupin Limited

Fresenius Kabi

B. Braun

USantibiotics

Qilu Pharmaceutical

ACS Dobfar

Nichi-Iko (Sagent)

Antibiotice

Beta-lactam and Beta-lactamase Inhibitors Segment by Type

Penicillins

Cephalosporins

Carbapenems

Monobactams

Combinations

Beta-lactam and Beta-lactamase Inhibitors Segment by Application

Oral

Intravenous

Beta-lactam and Beta-lactamase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Beta-lactam and Beta-lactamase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Beta-lactam and Beta-lactamase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Beta-lactam and Beta-lactamase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Beta-lactam and Beta-lactamase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Beta-lactam and Beta-lactamase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Penicillins Table 2. Major Company of Cephalosporins Table 3. Major Company of Carbapenems Table 4. Major Company of Monobactams Table 5. Major Company of Combinations Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 9. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 10. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2021-2026) Table 11. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 12. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2027-2032) & (M Units) Table 13. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 14. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 15. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2027-2032) Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 17. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 18. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 20. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 22. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 24. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (M Units) Table 26. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 27. Beta-lactam and Beta-lactamase Inhibitors Industry Trends Table 28. Beta-lactam and Beta-lactamase Inhibitors Industry Drivers Table 29. Beta-lactam and Beta-lactamase Inhibitors Industry Opportunities and Challenges Table 30. Beta-lactam and Beta-lactamase Inhibitors Industry Restraints Table 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Company (2021-2026) Table 33. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Company (2021-2026) & (M Units) Table 34. Global Beta-lactam and Beta-lactamase Inhibitors Sales Share by Company (2021-2026) Table 35. Global Beta-lactam and Beta-lactamase Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Beta-lactam and Beta-lactamase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Beta-lactam and Beta-lactamase Inhibitors Major Company Production Sites and Headquarters Table 38. Global Beta-lactam and Beta-lactamase Inhibitors Company, Product Type & Application Table 39. Global Beta-lactam and Beta-lactamase Inhibitors Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Beta-lactam and Beta-lactamase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Beta-lactam and Beta-lactamase Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2021-2026) & (M Units) Table 44. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 45. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 46. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Region (2021-2026) Table 47. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2027-2032) & (M Units) Table 49. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 50. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 51. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Region (2027-2032) Table 52. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 55. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 56. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 57. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2021-2026) Table 58. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 59. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2027-2032) & (M Units) Table 60. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 61. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 62. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2027-2032) Table 63. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 64. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 65. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 67. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 69. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 71. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (M Units) Table 73. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 78. Pfizer Recent Development Table 79. Novartis (Sandoz) Company Information Table 80. Novartis (Sandoz) Business Overview Table 81. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 83. Novartis (Sandoz) Recent Development Table 84. TEVA Company Information Table 85. TEVA Business Overview Table 86. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 88. TEVA Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merck Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 93. Merck Recent Development Table 94. AbbVie (Allergan) Company Information Table 95. AbbVie (Allergan) Business Overview Table 96. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 98. AbbVie (Allergan) Recent Development Table 99. Sumitomo Dainippon Company Information Table 100. Sumitomo Dainippon Business Overview Table 101. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 103. Sumitomo Dainippon Recent Development Table 104. Hikma Company Information Table 105. Hikma Business Overview Table 106. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 108. Hikma Recent Development Table 109. Aurobindo Pharma Company Information Table 110. Aurobindo Pharma Business Overview Table 111. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 113. Aurobindo Pharma Recent Development Table 114. Wockhardt Company Information Table 115. Wockhardt Business Overview Table 116. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 118. Wockhardt Recent Development Table 119. Lupin Limited Company Information Table 120. Lupin Limited Business Overview Table 121. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 123. Lupin Limited Recent Development Table 124. Fresenius Kabi Company Information Table 125. Fresenius Kabi Business Overview Table 126. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 128. Fresenius Kabi Recent Development Table 129. B. Braun Company Information Table 130. B. Braun Business Overview Table 131. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 133. B. Braun Recent Development Table 134. USantibiotics Company Information Table 135. USantibiotics Business Overview Table 136. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 138. USantibiotics Recent Development Table 139. Qilu Pharmaceutical Company Information Table 140. Qilu Pharmaceutical Business Overview Table 141. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 143. Qilu Pharmaceutical Recent Development Table 144. ACS Dobfar Company Information Table 145. ACS Dobfar Business Overview Table 146. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 148. ACS Dobfar Recent Development Table 149. Nichi-Iko (Sagent) Company Information Table 150. Nichi-Iko (Sagent) Business Overview Table 151. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 153. Nichi-Iko (Sagent) Recent Development Table 154. Antibiotice Company Information Table 155. Antibiotice Business Overview Table 156. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolio Table 158. Antibiotice Recent Development Table 159. North America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 160. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026) & (M Units) Table 161. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021-2026) Table 162. North America Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032) & (M Units) Table 163. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 164. North America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 166. North America Beta-lactam and Beta-lactamase Inhibitors Market Share by Country (2021-2026) Table 167. North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. North America Beta-lactam and Beta-lactamase Inhibitors Market Share Forecast by Country (2027-2032) Table 169. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 170. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026) & (M Units) Table 171. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021-2026) Table 172. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032) & (M Units) Table 173. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 174. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 175. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 176. Europe Beta-lactam and Beta-lactamase Inhibitors Market Share by Country (2021-2026) Table 177. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 178. Europe Beta-lactam and Beta-lactamase Inhibitors Market Share Forecast by Country (2027-2032) Table 179. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 180. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026) & (M Units) Table 181. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021-2026) Table 182. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032) & (M Units) Table 183. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 184. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 185. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 186. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Share by Country (2021-2026) Table 187. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 188. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Share Forecast by Country (2027-2032) Table 189. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 190. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026) & (M Units) Table 191. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021-2026) Table 192. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032) & (M Units) Table 193. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 194. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 195. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 196. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Share by Country (2021-2026) Table 197. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 198. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Share Forecast by Country (2027-2032) Table 199. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 200. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026) & (M Units) Table 201. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021-2026) Table 202. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032) & (M Units) Table 203. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 204. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 205. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 206. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Share by Country (2021-2026) Table 207. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 208. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Share Forecast by Country (2027-2032) Table 209. Key Raw Materials Table 210. Raw Materials Key Suppliers Table 211. Beta-lactam and Beta-lactamase Inhibitors Distributors List Table 212. Beta-lactam and Beta-lactamase Inhibitors Customers List Table 213. Research Programs/Design for This Report Table 214. Authors List of This Report Table 215. Secondary Sources Table 216. Primary Sources List of Figures Figure 1. Beta-lactam and Beta-lactamase Inhibitors Image Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Beta-lactam and Beta-lactamase Inhibitors Sales (2021-2032) & (M Units) Figure 5. Penicillins Image Figure 6. Global Penicillins Sales YoY Growth (2021-2032) & (M Units) Figure 7. Cephalosporins Image Figure 8. Global Cephalosporins Sales YoY Growth (2021-2032) & (M Units) Figure 9. Carbapenems Image Figure 10. Global Carbapenems Sales YoY Growth (2021-2032) & (M Units) Figure 11. Monobactams Image Figure 12. Global Monobactams Sales YoY Growth (2021-2032) & (M Units) Figure 13. Combinations Image Figure 14. Global Combinations Sales YoY Growth (2021-2032) & (M Units) Figure 15. Global Beta-lactam and Beta-lactamase Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Type 2025 VS 2032 Figure 17. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Beta-lactam and Beta-lactamase Inhibitors Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Oral Image Figure 30. Global Oral Sales YoY Growth (2021-2032) & (M Units) Figure 31. Intravenous Image Figure 32. Global Intravenous Sales YoY Growth (2021-2032) & (M Units) Figure 33. Global Beta-lactam and Beta-lactamase Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application 2025 VS 2032 Figure 35. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 46. North America Beta-lactam and Beta-lactamase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Beta-lactam and Beta-lactamase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 50. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Beta-lactam and Beta-lactamase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 54. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 58. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 62. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Beta-lactam and Beta-lactamase Inhibitors Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Penicillins
  • Cephalosporins
  • Carbapenems
  • Monobactams
  • Combinations
Applications
  • Oral
  • Intravenous
Companies covered
  • Pfizer
  • Novartis (Sandoz)
  • TEVA
  • Merck
  • AbbVie (Allergan)
  • Sumitomo Dainippon
  • Hikma
  • Aurobindo Pharma
  • Wockhardt
  • Lupin Limited
  • Fresenius Kabi
  • B. Braun
  • USantibiotics
  • Qilu Pharmaceutical
  • ACS Dobfar
  • Nichi-Iko (Sagent)
  • Antibiotice

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Beta-lactam and Beta-lactamase Inhibitors Market by Type
  6. 1.3.1 Penicillins
  7. 1.3.2 Cephalosporins
  8. 1.3.3 Carbapenems
  9. 1.3.4 Monobactams
  10. 1.3.5 Combinations
  11. 1.4 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
  12. 1.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends
  2. 2.2 Beta-lactam and Beta-lactamase Inhibitors Industry Drivers
  3. 2.3 Beta-lactam and Beta-lactamase Inhibitors Industry Opportunities and Challenges
  4. 2.4 Beta-lactam and Beta-lactamase Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Beta-lactam and Beta-lactamase Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Beta-lactam and Beta-lactamase Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Beta-lactam and Beta-lactamase Inhibitors Price (2021-2026)
  4. 3.4 Global Beta-lactam and Beta-lactamase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Beta-lactam and Beta-lactamase Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Beta-lactam and Beta-lactamase Inhibitors Company, Product Type & Application
  7. 3.7 Global Beta-lactam and Beta-lactamase Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Beta-lactam and Beta-lactamase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Beta-lactam and Beta-lactamase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Beta-lactam and Beta-lactamase Inhibitors Tier 1, Tier 2, and Tier 3
4 Beta-lactam and Beta-lactamase Inhibitors Regional Status and Outlook
  1. 4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Beta-lactam and Beta-lactamase Inhibitors by Application
  1. 5.1 Beta-lactam and Beta-lactamase Inhibitors Market by Application
  2. 5.1.1 Oral
  3. 5.1.2 Intravenous
  4. 5.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application
  5. 5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 Novartis (Sandoz)
  8. 6.2.1 Novartis (Sandoz) Company Information
  9. 6.2.2 Novartis (Sandoz) Business Overview
  10. 6.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  12. 6.2.5 Novartis (Sandoz) Recent Developments
  13. 6.3 TEVA
  14. 6.3.1 TEVA Company Information
  15. 6.3.2 TEVA Business Overview
  16. 6.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  18. 6.3.5 TEVA Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 AbbVie (Allergan)
  26. 6.5.1 AbbVie (Allergan) Company Information
  27. 6.5.2 AbbVie (Allergan) Business Overview
  28. 6.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  30. 6.5.5 AbbVie (Allergan) Recent Developments
  31. 6.6 Sumitomo Dainippon
  32. 6.6.1 Sumitomo Dainippon Company Information
  33. 6.6.2 Sumitomo Dainippon Business Overview
  34. 6.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  36. 6.6.5 Sumitomo Dainippon Recent Developments
  37. 6.7 Hikma
  38. 6.7.1 Hikma Company Information
  39. 6.7.2 Hikma Business Overview
  40. 6.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  42. 6.7.5 Hikma Recent Developments
  43. 6.8 Aurobindo Pharma
  44. 6.8.1 Aurobindo Pharma Company Information
  45. 6.8.2 Aurobindo Pharma Business Overview
  46. 6.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  48. 6.8.5 Aurobindo Pharma Recent Developments
  49. 6.9 Wockhardt
  50. 6.9.1 Wockhardt Company Information
  51. 6.9.2 Wockhardt Business Overview
  52. 6.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  54. 6.9.5 Wockhardt Recent Developments
  55. 6.10 Lupin Limited
  56. 6.10.1 Lupin Limited Company Information
  57. 6.10.2 Lupin Limited Business Overview
  58. 6.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  60. 6.10.5 Lupin Limited Recent Developments
  61. 6.11 Fresenius Kabi
  62. 6.11.1 Fresenius Kabi Company Information
  63. 6.11.2 Fresenius Kabi Business Overview
  64. 6.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  66. 6.11.5 Fresenius Kabi Recent Developments
  67. 6.12 B. Braun
  68. 6.12.1 B. Braun Company Information
  69. 6.12.2 B. Braun Business Overview
  70. 6.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  72. 6.12.5 B. Braun Recent Developments
  73. 6.13 USantibiotics
  74. 6.13.1 USantibiotics Company Information
  75. 6.13.2 USantibiotics Business Overview
  76. 6.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  78. 6.13.5 USantibiotics Recent Developments
  79. 6.14 Qilu Pharmaceutical
  80. 6.14.1 Qilu Pharmaceutical Company Information
  81. 6.14.2 Qilu Pharmaceutical Business Overview
  82. 6.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  84. 6.14.5 Qilu Pharmaceutical Recent Developments
  85. 6.15 ACS Dobfar
  86. 6.15.1 ACS Dobfar Company Information
  87. 6.15.2 ACS Dobfar Business Overview
  88. 6.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  90. 6.15.5 ACS Dobfar Recent Developments
  91. 6.16 Nichi-Iko (Sagent)
  92. 6.16.1 Nichi-Iko (Sagent) Company Information
  93. 6.16.2 Nichi-Iko (Sagent) Business Overview
  94. 6.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  96. 6.16.5 Nichi-Iko (Sagent) Recent Developments
  97. 6.17 Antibiotice
  98. 6.17.1 Antibiotice Company Information
  99. 6.17.2 Antibiotice Business Overview
  100. 6.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
  102. 6.17.5 Antibiotice Recent Developments
7 North America by Country
  1. 7.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  2. 7.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country
  6. 7.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  2. 8.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country
  6. 8.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  2. 10.1.1 South America Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country
  6. 10.2.1 South America Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Beta-lactam and Beta-lactamase Inhibitors Value Chain Analysis
  2. 12.1.1 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process
  7. 12.2 Beta-lactam and Beta-lactamase Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Beta-lactam and Beta-lactamase Inhibitors Distributors
  10. 12.2.3 Beta-lactam and Beta-lactamase Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst